In a recent episode of Shark Tank India 4, founders Dheeraj Nagpal and Sachin Goel of Zinga Vita delivered an entertaining pitch centered around Shilajit, an ayurvedic supplement known for its multiple health benefits. Their mission was to destigmatize Shilajit and highlight its uses beyond sexual wellness, including improved metabolism, boosted energy levels, and benefits for both men and women.
The duo sought an investment of ₹1 crore for 1.25% equity, valuing their startup at ₹80 crore. While the product intrigued the judges, it also led to humorous exchanges. Aman Gupta quipped, “Aap ne sab Shilajit banaye hain, Shilajit, Shilajit (You’ve made everything out of Shilajit),” and humorously declined a taste of Shilajit honey, saying, “Ye humein nahi zaroorat” (I don’t need this).
Concerns Over Pricing and Efficacy
As the pitch progressed, the sharks raised serious concerns. Ritesh Agarwal questioned the high pricing of the products, while Kunal Bahl dismissed their strategy with a blunt remark, “Aapko lagta hai ye saman bik raha hai market mein toh hum bhi bech le” (You thought since this product is selling in the market, let’s sell it too).
The lack of clinical trials and data supporting the claims proved to be a major stumbling block. Namita Thapar and Vineeta Singh emphasized the need for evidence-based research to substantiate the product’s benefits, such as increased energy, strength, and muscle gain. “Focus on fundamentals and base it on evidence,” advised Namita.
Sharks Bow Out
Despite the founders’ defense of their product and claims of success in international markets, their high return-to-origin (RTO) rates and lack of clinical validation led the sharks to decline the investment. Aman Gupta highlighted issues with their burn rates, reinforcing that the road to success would require a stronger foundation.
The Takeaway
While Zinga Vita’s pitch brought laughter and lighthearted moments to the show, it also underscored the importance of clinical validation and a clear market strategy in gaining investor confidence. The duo may not have secured a deal, but their efforts to normalize conversations around Shilajit mark a step forward in breaking taboos in India.
